Late Breaker: The start of respiratory season is here! Unfortunately, for this RSV season there is limited supply of the new monoclonal antibody nirsevimab. To address this concern, the CDC issued a HAN last week recommending prioritizing giving this preventative therapy to infants at highest risk for severe RSV disease, including infants < 6 months of age, American Indian and Alaska Native infants < 8 months of age, and infants 6 to < 8 months of age with underlying medical conditions that place them at high risk for severe RSV disease. More information can be found at: https://emergency.cdc.gov/han/2023/han00499.asp